We are happy to share that HALO Diagnostics, Inc. (HALO Dx) will  evaluate the safety and short term efficacy of CLS’s TRANBERG® Thermal Therapy System for treating low-to-medium risk prostate cancer patients.

HALO will conduct an initial postmarket study treating up to twenty-five (25) patients at one or more of its HALO Ambulatory Surgery Centers in the US. Upon completion of its evaluation, HALO and CLS will enter into discussions regarding HALO’s acquisition of the TRANBERG system for use in some of its nationwide system of approximately 16 clinics.

“CLS Americas is excited to begin this initial collaboration with HALO Diagnostics to bring our minim-ally invasive, image-guided FLA treatment to patients in the convenience of their local urology doctor’s office or clinic,” said Michael Magnani, President of CLS Americas, Inc. “We share a common goal with HALO to enable and deliver a safe and effective treatment of prostate cancer that also helps preserve a patient’s quality of life.”

“HALO Precision Diagnostics is pleased to announce a formal relationship and initial post-market
study with CLS to evaluate its TRANBERG system for treating patients with image-guided, laser focal therapy,” stated Bernadette M. Greenwood, Chief Research Officer, HALO Diagnostics, Inc. “CLS has a strong track record of safety and innovation with its TRANBERG system and a history of successful clinical studies with leading academic and research institutions in the US and EU. We look forward to working with their team to help more patients access focal therapy.”

Read the full press release here.